A Randomized Trial to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa

Trial Profile

A Randomized Trial to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs RVSV-S-GP/VP40 vaccine (Primary)
  • Indications Ebola virus infections
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 18 Oct 2016 According to International Development Research Centre media release, final results expected later in fall 2016.
    • 21 Jul 2016 Status changed from recruiting to completed.
    • 29 Aug 2015 Interim results for rVSV-S-GP/VP40-vaccine in 7651 patients published in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top